Vogt Benoît, Blanchet Laure-Hélène
Department of Urology, Polyclinique de Blois, La Chaussée Saint-Victor, 41260, France.
Department of Public Health, Hôpital Saint-Antoine (AP-HP), Paris, 75012, France.
Res Rep Urol. 2021 Oct 27;13:773-782. doi: 10.2147/RRU.S334277. eCollection 2021.
Ureteral obstruction hinders the management of malignant diseases. Adequate stent placement does not necessarily guarantee renal decompression. The stent stiffness may play a major role to maintain patency. We carried out the present study in order to evaluate drainage efficiency by using stents with distinctive degrees of stiffness and to identify the physical factors that could prevent obstruction of the stent in patients with malignant ureteral obstruction (MUO).
We performed an analysis of 150 patients with MUO drainage at a single institution from June 2009 to June 2019. A progressive choice of stents was shaped to overcome each failure by focusing on the criterion of increasingly stiff stents.
During the study period, 556 ureteral stent procedures (USP) were analysed separately. The stent failure with obstruction occurred in 23.0% (128/556) of USP at a mean of 4.4±3.6 months and depended on the type of stent. Stent failure occurred in 34.2% (70/205) of Vortek stents, in 42.9% (15/35) of Urosoft stents, in 15.4% (39/254) of Superglide or ureteral catheters and in 6.5% (4/62) of tandem stents. No significant differences were found between Vortek and Urosoft stents regarding stent failures, but there were significant differences between Superglide or Tandem stents and Vortek or Urosoft stents (p<10). The study demonstrated that ureteral stent obstruction significantly decreased with a larger lumen or a stiffer stent (p<10).
In the present study, Superglide and tandem stents were the best stents against stent failure, and the lumen and the stiffness of the stent have been shown to be critical factors in controlling patency. The results suggest that the lumen seems more important than the stiffness, and the stiffness would be the only means of keeping the lumen intact. Future stents for MUO should integrate the importance of the lumen of the stent.
输尿管梗阻会妨碍恶性疾病的治疗。放置合适的支架不一定能保证肾脏减压。支架的硬度可能对维持通畅起着主要作用。我们开展本研究是为了评估使用不同硬度的支架的引流效率,并确定可预防恶性输尿管梗阻(MUO)患者支架梗阻的物理因素。
我们对2009年6月至2019年6月在一家机构进行MUO引流的150例患者进行了分析。通过聚焦于支架硬度逐渐增加的标准,形成了一种渐进式的支架选择方式,以克服每次失败。
在研究期间,对556例输尿管支架置入术(USP)进行了单独分析。梗阻导致的支架失败发生在23.0%(128/556)的USP中,平均发生时间为4.4±3.6个月,且取决于支架类型。Vortek支架的失败率为34.2%(70/205),Urosoft支架为42.9%(15/35),Superglide或输尿管导管为15.4%(39/254),串联支架为6.5%(4/62)。Vortek支架和Urosoft支架在支架失败方面未发现显著差异,但Superglide或串联支架与Vortek或Urosoft支架之间存在显著差异(p<0.01)。研究表明,随着管腔增大或支架变硬,输尿管支架梗阻显著减少(p<0.01)。
在本研究中,Superglide和串联支架是预防支架失败的最佳支架,且已证明支架的管腔和硬度是控制通畅的关键因素。结果表明管腔似乎比硬度更重要,而硬度将是保持管腔完整的唯一手段。未来用于MUO的支架应整合支架管腔的重要性。